Explore TC BioPharm's recent Form 6-K filing detailing the ADS ratio change, trading impacts, and warrant adjustments, essential for investors and stakeholders.
Explore TC Biopharm's Form 6-K detailing a special dividend of 0.25 ADSs and warrant adjustments for January 2025.
Explore TC Biopharm's compliance challenges with Nasdaq, including its response to a delisting notification and plans for a hearing to maintain its market listing.
Discover TC Biopharm (Holdings) PLC's special dividend announcement, shareholder approval, and trading updates in this concise 6-K financial report overview.
TC BioPharm's December 2024 meeting highlights key resolutions on bonus shares and equity financing, showcasing strong shareholder support and strategic growth plans.
Explore TC Biopharm's December 2024 financial report detailing a $14M ATM offering agreement with H.C. Wainwright & Co. for American Depositary Shares (ADSs).